Key result
WCD prevents recurrent VF and bridges a patient with cardiac DLBCL relapse to salvage chemotherapy.
Why the study?
There is a lack of published data on cardiac involvement within myeloid neoplasia, for which treatment can rapidly improve cardiac function, making the wearable cardioverter defibrillator an option to bridge patients.
Does a wearable cardioverter defibrillator prevent sudden cardiac death in a hematologic patient with cardiac involvement?
Case Report (n=1)
Does a wearable cardioverter defibrillator prevent sudden cardiac death in a hematologic patient with cardiac involvement?
A wearable cardioverter defibrillator can be effectively used as a bridge to prevent sudden cardiac death in hematologic patients with potentially reversible cardiac involvement.
May support WCD bridging in reversible cardiac involvement; hypothesis-generating for hematologic malignancy patients and requires prospective validation.
The implantable cardioverter defibrillator (ICD) is a cornerstone in the prevention of sudden cardiac death in patients with cardiomyopathy as well as survivors of idiopathic ventricular arrhythmias. The indications for this device are strict and exclude patients with a limited expected lifespan as well as patients with an expected improvement of cardiac function [ 1 ]. Cardiac involvement or sudden cardiac death within hematologic diseases is a rare finding. In a large autopsy study, 8% of patients deceased due to a lymphatic malignancy showed cardiac involvement [ 2 ]. There is a lack of published data of cardiac involvement within myeloid neoplasia. Only case reports on this topic are available [ 3 , 4 ]. The vast majority of cases can be effectively treated by initiation of a specific therapy, leading to a rapid improvement of cardiac function and preventing sudden cardiac death [ 5 ]. The wearable cardioverter defibrillator (WCD) is a well-established opportunity to bridge such patients [ 6 ].
No takes yet. Share an insight, caveat, or question.
Hatzl et al. (2019) conducted a case report in Cardiac relapse of diffuse large B-cell lymphoma with ventricular fibrillation (n=1). Wearable cardioverter defibrillator (WCD) was evaluated on Prevention of further life-threatening arrhythmias. The use of a wearable cardioverter defibrillator successfully prevented further episodes of ventricular fibrillation and bridged a patient with cardiac relapse of DLBCL to salvage chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: